



an Open Access Journal by MDPI

Molecular Mechanism in Retinal Diseases

Guest Editors:

Dr. Ming Yang

Department of Ophthalmology,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong,
Hong Kong 999077, China

Prof. Dr. Ching-Lung Lai

Faculty Of Medicine, University of
Hong Kong, Hong Kong, China

Dr. Michael Zhipeng Yan

Department of Medicine, Queen
Mary Hospital, The University of
Hong Kong, Hong Kong, China

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

Vision formation relies heavily on the retina; however, light-sensitive tissue damage tends to cause retinal diseases such as retinal degeneration, retinal detachment, and diabetic retinopathy. Though efforts have been made to address these problems, the therapeutic options for many retinal diseases are still limited. Therefore, better understanding of the underlying mechanisms would greatly benefit future treatment development.

Based on the essential character of the mitochondrion, the regulation of mitochondrion-associated cell death might have enormous therapeutic potential in various retinal diseases. Although the implications of mitochondrion-associated cell death have been addressed in various diseases, its role and use as a therapeutic target in retinal diseases are still poorly understood.

This Special Issue focuses on the molecular mechanisms of retinal diseases, including the contribution of mitochondrion-associated cell death to pathology. Manuscripts presenting other molecular mechanisms and therapeutic interventions and strategies for retinal diseases are also welcome.



mdpi.com/si/157364

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI